Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
doi: 10.3978/j.issn.1000-9604.2015.02.07 6 LiuYHuYJiangYBuJGuX
As the field moves toward integrative disease models and precision medicine, neuroendocrine and immunemetabolic peptides may represent a critical frontier for therapeutic innovation
Activating GLP-1, GIP, and glucagon receptors simultaneously puts more stress on the gastrointestinal system during the adaptation period
ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy
It is known that the CV protection effect of GLP-1RAs have been proven through eight large-scale clinical studies, including Evaluation of LIXisenatide in Acute coronary syndrome (ELIXA) [66], LEADER [44], Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN)-6 [67], Exenatide Study of Cardiovascular Event Lowering (EXSCEL) [68], Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes) [69], Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) [70], Peptide Innovation for Early Diabetes Treatment (PIONEER) 6 [67,71], and AMPLITUDE-O [51]
